IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

Objectives: The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients. Recently, a functional variant, ss469415590, in linkage disequilibrium (LD) with...

Descripción completa

Detalles Bibliográficos
Autores: Real, Luis M.|||0000-0003-4932-7429, Neukam, Karin, Herrero del Rio, Mª del Rocío|||0000-0002-9678-0309, Guardiola, Josep M., Reiberger, Thomas|||0000-0002-4590-3583, Rivero-Juarez, Antonio|||0000-0002-5813-6889, Salazar, Juliana|||0000-0002-3581-4499, Mandorfer, Mattias|||0000-0003-2330-0017, Merino, Dolores, Soriano, Vicente|||0000-0002-4624-5199, Rivero Román, Antonio|||0000-0002-8643-4250, Macías, Juan|||0000-0002-4778-790X, Pineda, Juan A.|||0000-0002-3751-0296, Caruz, Antonio
Tipo de recurso: artículo
Fecha de publicación:2014
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:302464
Acceso en línea:https://ddd.uab.cat/record/302464
https://dx.doi.org/urn:doi:10.1371/journal.pone.0095515
Access Level:acceso abierto
Palabra clave:Adult
Alleles
Antiviral Agents
Coinfection
European Continental Ancestry Group
Female
Follow-Up Studies
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interleukins
Male
Middle Aged
Polymorphism, Single Nucleotide
ROC Curve
Treatment Outcome
Descripción
Sumario:Objectives: The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients. Recently, a functional variant, ss469415590, in linkage disequilibrium (LD) with rs12979860, has been discovered. Our objective was to assess the value of ss469415590 to predict SVR to pegIFN/RBV in Caucasian HCV-1/4-infected individuals and to compare its performance with that of rs12979860. Methods: 272 Caucasian HCV-1/4-infected patients who completed a course of pegIFN/RBV were genotyped for both rs12979860 and ss469415590 markers. Logistic regression models including factors with univariate association with SVR and each genetic marker were elaborated. The area under the receiver operating-characteristic curve (AUROC) was calculated for each model and both were compared. Results: Both markers were in LD (r = 0.82). For rs12979860, 66 (64.0%) CC versus 56 (33.1%) T allele carriers achieved SVR (Adjusted OR = 4.156, 95%CI = 2.388-7.232, p = 4.647×10). For ss469415590, 66 (66.0%) TT/TT versus 56 (32.5%) -G allele carriers (Adjusted OR = 4.783, 95% CI = 2.714-8.428, p = 6.153×10) achieved SVR. The AUROC of the model including rs12979860 was 0.742 (95%CI = 0.672-0.813) and of that based on ss469415590 was 0.756 (95%CI = 0.687-0.826) (p = 0.780). Conclusions: The ss469415590 variant shows an equivalent performance to predict SVR to pegIFN/RBV than the rs2979860 in Caucasian HCV-1/4-infected patients. © 2014 Real et al.

Similares en LA Referencia